10 mg BID, based on 4-week GLP rat and dog toxicology studies
“The starting dose of asciminib for patients with CML-CP/-AP selected for the dose escalation part of this study was set at 10 mg orally administered BID under fasted conditions. The selection of the starting dose of asciminib was based on 4-week GLP toxicology studies conducted in rats and dogs.”
✓ VerifiedFDA multi-discipline review, p. 165Source ↗
NOAEL / key findings
Target organs: hematopoietic system, liver, kidney, adrenal gland, GI tract, and pancreas (dog only)
“The general toxicology studies identified toxicities in the hematopoietic system, liver, kidney, adrenal gland, gastro-intestinal (GI) tract, and pancreas (dog only).”
✓ VerifiedFDA multi-discipline review, p. 39Source ↗